Immunochem Therapeutics LLC
Newton, MA
- UEI
- SCDHKSSUC4T4
- CAGE
- 7KKW6
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- SAM.gov registration date
- Physical address
- 105 Auburn St, Auburndale, MA 02466, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Cornovus Pharmaceuticals Inc. | New Haven, CT | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Seak Therapeutics, LLC | Memphis, TN | — |
| Alcamena Stem Cell Therapeutics, LLC | Spencerville, MD | 621511 Medical Laboratories |
| Acepre, LLC | Columbia, SC | 325412 Pharmaceutical Preparation Manufacturing |
| Neurano Bioscience LLC | Encinitas, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Immunochem Therapeutics LLC is a for-profit limited liability company that has been registered in SAM.gov since 2016 to receive federal awards. It provides pharmaceutical research and development services focused on novel anti-neuroinflammatory drugs.
Through prime federal grant awards from the National Institutes of Health, Immunochem Therapeutics has conducted research to develop MW189, an experimental therapeutic intended to treat aneurysmal subarachnoid hemorrhage, drug-resistant epilepsy, and mitigate radiation therapy-induced neuroinflammation and cognitive dysfunction in cancer patients. Specific activities funded include preclinical efficacy studies in animal models, preparing regulatory documentation and meeting milestones for Investigational New Drug applications, and conducting a clinical feasibility study of MW189 as an adjunct therapy to whole brain radiation treatment for brain metastases patients. In total, Immunochem Therapeutics has been awarded over $7.5 million in federal grants from the National Institute of Neurological Disorders and Stroke, National Institute on Aging, and National Cancer Institute since 2019.
Quick answers
Is Immunochem Therapeutics LLC registered in SAM.gov?
Yes. Immunochem Therapeutics LLC's SAM.gov registration is active through October 8, 2027.
What is Immunochem Therapeutics LLC's most recent federal award?
Immunochem Therapeutics LLC's most recent federal grant award is (no IDC) advancing an experimental antineuroinflammatory drug toward a phase 2A clinical trial in traumatic brain injury (HT9425261E262), from Defense Health Agency, on August 1, 2026.
On GovTribe
See Immunochem Therapeutics LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors